Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis

被引:48
|
作者
Fuster-Matanzo, Almudena [1 ,3 ]
Llorens-Martin, Maria [1 ,3 ]
Salome Sirerol-Piquer, Maria [2 ,3 ]
Manuel Garcia-Verdugo, Jose [2 ,3 ]
Avila, Jesus [1 ,3 ]
Hernandez, Felix [1 ,3 ]
机构
[1] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain
[2] Univ Valencia, Inst Cavanilles, Dept Neurobiol Comparada, Valencia 46980, Spain
[3] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid 28031, Spain
关键词
LONG-TERM POTENTIATION; NEURAL STEM-CELLS; HIPPOCAMPAL NEUROGENESIS; ALZHEIMERS-DISEASE; MOUSE MODEL; TAU-HYPERPHOSPHORYLATION; CHEMOKINE RECEPTORS; PROGENITOR CELLS; NEURONAL DEATH; BETA-CATENIN;
D O I
10.1093/hmg/dds533
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Adult neurogenesis, the generation of new neurons during the adulthood, is a process controlled by several kinases and phosphatases among which GSK3 beta exerts important functions. This protein is particularly abundant in the central nervous system, and its activity deregulation is believed to play a key role in chronic disorders such as Alzheimers disease. Previously, we reported that in vivo overexpression of GSK3 beta (Tet/GSK3 beta mice) causes alterations in adult neurogenesis, leading to a depletion of the neurogenic niches. Here, we have further characterized those alterations, finding a delay in the switching-off of doublecortin marker as well as changes in the survival and death rates of immature precursors and a decrease in the total number of mature neurons. Besides, we have highlighted the importance of the inflammatory environment, identifying eotaxin as a possible modulator of the detrimental effects on adult neurogenesis. Taking advantage of the conditional system, we have also explored whether these negative consequences of increasing GSK3 activity are susceptible to revert after doxycycline treatment. We show that transgene shutdown in symptomatic mice reverts microgliosis, abnormal eotaxin levels as well as the aforementioned alterations concerning immature neurons. Unexpectedly, the decrease in the number of mature neurons and neuronal precursor cells of the subgranular zone of Tet/GSK3 beta mice could not be reverted. Thus, alterations in adult neurogenesis and likely in neurodegenerative disorders can be restored in part, although neurogenic niche depletion represents a non-reversible damage persisting during lifetime with a remarkable impact in adult mature neurons.
引用
收藏
页码:1300 / 1315
页数:16
相关论文
共 50 条
  • [1] Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors
    Avila, Jesus
    Wandosell, Francisco
    Hernandez, Felix
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (05) : 703 - 710
  • [2] Glycogen synthase kinase-3 as a key regulator of cognitive function
    Fan, Xuhong
    Zhao, Zhenyu
    Wang, Deming
    Xiao, Ji
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2020, 52 (03) : 219 - 230
  • [3] Glycogen Synthase Kinase-3β2 Has Lower Phosphorylation Activity to Tau than Glycogen Synthase Kinase-3β1
    Saeki, Kazunori
    Machida, Mayumi
    Kinoshita, Yutaro
    Takasawa, Ryoko
    Tanuma, Sei-ichi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2011, 34 (01) : 146 - 149
  • [4] Identification of Glycogen Synthase Kinase-3 Inhibitors with a Selective Sting for Glycogen Synthase Kinase-3α
    Lo Monte, Fabio
    Kramer, Thomas
    Gu, Jiamin
    Anumala, Upendra Rao
    Marinelli, Luciana
    La Pietra, Valeria
    Novellino, Ettore
    Franco, Benedicte
    Demedts, David
    Van Leuven, Fred
    Fuertes, Ana
    Manuel Dominguez, Juan
    Plotkin, Batya
    Eldar-Finkelman, Hagit
    Schmidt, Boris
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (09) : 4407 - 4424
  • [5] Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments
    King, Margaret K.
    Pardo, Marta
    Cheng, Yuyan
    Downey, Kimberlee
    Jope, Richard S.
    Beurel, Eleonore
    PHARMACOLOGY & THERAPEUTICS, 2014, 141 (01) : 1 - 12
  • [6] THE EFFECTS OF NEUROPSYCHIATRIC DRUGS ON GLYCOGEN SYNTHASE KINASE-3 SIGNALING
    Sutton, L. P.
    Rushlow, W. J.
    NEUROSCIENCE, 2011, 199 : 116 - 124
  • [7] Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder
    Dandekar, Manoj P.
    Valvassori, Samira S.
    Dal-Pont, Gustavo C.
    Quevedo, Joao
    CURRENT DRUG METABOLISM, 2018, 19 (08) : 663 - 673
  • [8] Glycogen synthase kinase-3 and alternative splicing
    Liu, Xiaolei
    Klein, Peter S.
    WILEY INTERDISCIPLINARY REVIEWS-RNA, 2018, 9 (06)
  • [9] Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease
    Fernandez-Nogales, Marta
    Hernandez, Felix
    Miguez, Andres
    Alberch, Jordi
    Gines, Silvia
    Perez-Navarro, Esther
    Lucas, Jose J.
    HUMAN MOLECULAR GENETICS, 2015, 24 (17) : 5040 - 5052
  • [10] Deletion of Glycogen Synthase Kinase-3β in Cartilage Results in Up-Regulation of Glycogen Synthase Kinase-3α Protein Expression
    Gillespie, J. R.
    Ulici, V.
    Dupuis, H.
    Higgs, A.
    DiMattia, A.
    Patel, S.
    Woodgett, J. R.
    Beier, F.
    ENDOCRINOLOGY, 2011, 152 (05) : 1755 - 1766